With a Senate vote looming and reports of an impending White House proposal, this article discusses what has transpired in ...

With the Supreme Court’s new term fully underway, we reflect on the most recent term, which concluded in June. In addition to ...

Health Affairs' Rob Lott interviews Tiffany Lemon of Arizona State University on her recent paper exploring the concept of ...

As policy makers pursue price transparency, they should consider what additional measures could serve as a complement to ...

In late 2024, the Centers for Medicare and Medicaid Services previewed a significant revision to the risk-adjustment model ...

The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...

In this piece, we explore reasons for creating a separate conversion factor within the MPFS, initially for advanced primary ...

The real gold standard for science, and academic freedom, requires upholding scientific work that investigates who and what ...

We aim to provide transparency in how Elevance Health plans address variations in clinical practices to ensure safe, ...

When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.

The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...

In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...